UroGen Pharma Ltd. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
UroGen Pharma Ltd. (URGN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $4.82 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $4.82M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $5.01M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $5.38M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $5.39M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $4.82M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.01M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $5.38M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.39M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.34M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $4.11M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.29M 10-K · filed 2026-03-02 |
| 2023-12-31 | $1.67M 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |